Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences


Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will participate in a Truist Virtual Fireside Chat, the Guggenheim Virtual Conference: 2nd Annual Neuro/Immunology Day and the Jefferies Global Healthcare Conference over the next few weeks.

Additional details can be found below:

Truist Virtual Fireside Chat
Friday, October 23, 2020
Time: 12:30 PM Eastern Time
Fireside chat with Joon Lee, M.D., Ph.D., Equity Analyst and Dr. Scott Braunstein, Chief Executive Officer, Ed Smith, Chief Financial Officer, and Dr. Joseph Hulihan, Chief Medical Officer
For registration and webcast details, see: https://www.netroadshow.com/events/login?show=6debe4f7&confId=25029

Guggenheim Healthcare Talks - Idea Forum | 2nd Annual Neuro/Immunology Day
Monday, November 16, 2020
One-on-one meetings with Marinus executives

Jefferies London Healthcare Conference
Wednesday, November 18, 2020
Fireside chat with Andrew Tsai, Equity Analyst and Dr. Scott Braunstein, Chief Executive Officer, Ed Smith, Chief Financial Officer, and Dr. Joseph Hulihan, Chief Medical Officer
One-on-one meetings with Marinus executives; for registration and webcast details, see: https://wsw.com/webcast/jeff141/mrns/1869600

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company intends to initiate a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.


These press releases may also interest you

at 14:20
TDS and UScellular to release first quarter operating results and host conference call on May 3, 2024
Telephone and Data Systems, Inc. and United States Cellular Corporation  will be webcasting their first quarter operating results conference call on May 3, 2024, at 9:00 a.m. Central Time.  The companies will release their financial results on May...

at 14:17
AdminaHealth's New Employee Benefits Payroll Reconciliation Feature Disrupts the Status Quo
AdminaHealth®, the leading provider of Software-as-a-Service (SaaS) solutions for employee benefits billing and payment, today announced the expansion of the AdminaHealth Billing Suite® payroll comparison capabilities with its new patented "Pay As...

at 14:15
"BEYOND THE VEIL" RENEWED FOR A SECOND SEASON ON AMAZON PRIME VIDEO
In the competitive landscape of streaming services, 'Beyond the Veil' Season 2, the highly anticipated continuation of the hit series, is set to premiere on June 7th, 2024, on Prime Video. Speaking on the highly anticipated show, Showrunner Nadine...

at 14:05
YC-Backed Yoneda Labs Raises $4 Million Seed Led by Khosla Ventures to Build Foundation Model for Chemists
Yoneda Labs, the Y Combinator startup building a foundation model for chemists working in drug discovery, today announced it has raised $4 million in seed capital from Khosla Ventures, 500 Emerging Europe, 468 Capital, Fellows Fund, and Y Combinator....

at 14:02
doxo Responds to U.S. Federal Trade Commission's Misguided Litigation
Yesterday, the U.S Federal Trade Commission filed a lawsuit against doxo, a company working to deliver a better bill-paying experience for consumers and billers, with a complaint that indicates a fundamental misunderstanding of the existing bill-pay...

at 14:00
Bailey & Galyen Obtains $3 Million Verdict in Railway Attack Case Against Allied Universal Security Services
Attorneys Scott Robelen and Clint Lee, of Bailey & Galyen Attorneys at Law, achieved a $3 million award for their client, John Farley, in a case against Allied Universal Security Services. Farley, a 39-year-old conductor, was brutally attacked at the...

More news about Science and technology...


News published on and distributed by: